Transferring to another type or brand, changes in strength, species &/or method of manufacture of insulin. Less pronounced or different early warning symptoms of hypoglycemia in conditions including long duration of diabetes, diabetic nerve disease, medications (eg, β-blockers). Uncorrected hypoglycemic & hyperglycemic reactions. Inadequate use of dosages or discontinuation of treatment may lead to hyperglycemia & diabetic ketoacidosis especially in insulin-dependent diabetics. Insulin requirements may be changed significantly in diseases of the adrenal, pituitary, or thyroid glands & in presence of renal or hepatic impairment; may be increased during illness or emotional disturbances. Observe for signs & symptoms of heart failure, wt gain & edema if used in combination w/ pioglitazone; discontinue pioglitazone if any deterioration in cardiac symptoms occurs. Instruct patients to perform continuous rotation of the inj site to reduce the risk of developing lipodystrophy & cutaneous amyloidosis. Monitor blood glucose after the change in the inj site & consider adjusting dose of antidiabetics. May impair ability to drive or operate machinery. Pregnancy & lactation.
A10AD01 - insulin (human) ; Belongs to the class of intermediate-acting combined with fast-acting insulins and analogues. Used in the treatment of diabetes.
Sign Out
